Document Detail

Retinal nerve fiber layer thickness in patients receiving chronic anti-vascular endothelial growth factor therapy.
MedLine Citation:
PMID:  20643396     Owner:  NLM     Status:  MEDLINE    
PURPOSE: To evaluate the effects of multiple intravitreal injections of anti-vascular endothelial growth factor (VEGF) agents on the thickness of the retinal nerve fiber layer (RNFL) in patients with wet age-related macular degeneration (ARMD).
DESIGN: Retrospective, observational, consecutive case series of patients diagnosed with wet ARMD.
METHODS: Forty-one eyes of 37 consecutive patients (25 female and 12 male; mean age 79.2 ± 8.7 years) who underwent treatment with pegaptanib, bevacizumab, and/or ranibizumab for ARMD followed by sequential RNFL thickness measurement by optical coherence tomography (OCT) were studied. Patients were included in the analyses if they had greater than 10 total anti-VEGF injections, RNFL measurements prior to the first injection, and at least 12 months of follow-up. Patients were divided into 3 groups depending on which anti-VEGF agent(s) they received. The OCT RNFL measurements at the initial and final follow-up were used for analyses.
RESULTS: Average follow-up for all patients was 27.0 ± 9.7 months and they received an average of 16.0 ± 5.5 intravitreal injections. The average RNFL thickness at presentation was 92.4 ± 15.2 μm and at last follow-up was 93.8 ± 15.2 μm (P = .68). There were no statistically significant differences in RNFL measurements when comparing between individual anti-VEGF treatment groups.
CONCLUSION: Long-term treatment with anti-VEGF agents did not lead to significant changes in RNFL thickness in a patient population with wet ARMD. Despite the possibility of repeated intraocular pressure (IOP) fluctuations after intravitreal injections and known neurotrophic properties of VEGF in the eye, chronic therapy with intravitreal anti-VEGF agents does not appear to adversely affect RNFL thickness. Further prospective studies with longer follow-up are needed to corroborate the findings of this study.
Michael B Horsley; Naresh Mandava; Marco A Maycotte; Malik Y Kahook
Related Documents :
24507986 - Impact of tricuspid regurgitation after redo valvular surgery on survival in patients w...
15513446 - Combining photodynamic therapy and feeder vessel photocoagulation: a pilot study.
12928276 - Severe infective keratitis leading to hospital admission in new zealand.
20446536 - A case series of symptomatic ocular tuberculosis and the response to anti-tubercular th...
9856256 - Systemic antibiotic therapy on multiple intracerebral abscesses of unknown origin.
20453546 - Randomized controlled trial of hyaluronic acid/carboxymethylcellulose dressing after en...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  American journal of ophthalmology     Volume:  150     ISSN:  1879-1891     ISO Abbreviation:  Am. J. Ophthalmol.     Publication Date:  2010 Oct 
Date Detail:
Created Date:  2010-09-24     Completed Date:  2010-10-06     Revised Date:  2013-05-27    
Medline Journal Info:
Nlm Unique ID:  0370500     Medline TA:  Am J Ophthalmol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  558-561.e1     Citation Subset:  AIM; IM    
Copyright Information:
Copyright © 2010 Elsevier Inc. All rights reserved.
Rocky Mountain Lions Eye Institute, Department of Ophthalmology, University of Colorado Denver School of Medicine, Aurora, CO 80045, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Angiogenesis Inhibitors / administration & dosage*,  adverse effects
Antibodies, Monoclonal / administration & dosage,  adverse effects
Antibodies, Monoclonal, Humanized
Aptamers, Nucleotide / administration & dosage,  adverse effects
Nerve Fibers / drug effects,  pathology*
Optic Disk / drug effects,  pathology*
Retinal Ganglion Cells / drug effects,  pathology*
Retrospective Studies
Tomography, Optical Coherence
Vascular Endothelial Growth Factor A / antagonists & inhibitors*
Vitreous Body
Wet Macular Degeneration / drug therapy*
Reg. No./Substance:
0/Angiogenesis Inhibitors; 0/Antibodies, Monoclonal; 0/Antibodies, Monoclonal, Humanized; 0/Aptamers, Nucleotide; 0/VEGFA protein, human; 0/Vascular Endothelial Growth Factor A; 0/pegaptanib; 0/ranibizumab; 2S9ZZM9Q9V/bevacizumab
Comment In:
Am J Ophthalmol. 2011 Feb;151(2):384; author reply 384-5   [PMID:  21251500 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Incidence rates and risk factors for ocular complications and vision loss in HLA-B27-associated uvei...
Next Document:  Plus disease in retinopathy of prematurity: quantitative analysis of vascular change.